PDF herunterladen
Semin Respir Crit Care Med 2003; 24(5): 499-530
DOI: 10.1055/s-2004-815601
Copyright © 2003 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Bronchiolitis Obliterans Syndrome Complicating Lung or Heart-Lung Transplantation

John A. Belperio1 , Kathleen Lake2 , Henry Tazelaar3 , Michael P. Keane1 , Robert M. Strieter1 , Joseph P. Lynch, III1
  • 1Department of Medicine, Division of Pulmonary and Critical Care Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, California
  • 2Department of Medicine, Division of Nephrology, University of Michigan Medical Center, Ann Arbor, Michigan
  • 3Department of Pathology, Mayo Clinic, Rochester, Minnesota
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
15. Januar 2004 (online)

    Lizenzen und Reprints

ABSTRACT

Lung transplantation is a therapeutic option for patients with end stage lung diseases, but long-term survival remains poor, primarily due to chronic allograft rejection. Bronchiolitis obliterans (BO), a fibrotic process resulting in progressive narrowing of bronchiolar lumens and airflow obstruction, is a manifestation of chronic allograft rejection. The term obliterative bronchiolitis (OB) is synonymous. Once bronchiolitis obliterans syndrome (BOS) develops, progressive decline in pulmonary function is typical; most patients die of respiratory failure within 5 years of onset. The diagnosis of BOS is usually made by clinical, physiological, and radiographic parameters. The dominant risk factor for BOS is acute allograft rejection, but additional factors play contributory roles [e.g., infections; human leukocyte antigen (HLA) mismatching; and injury to the allograft or airways]. The pathogenesis of BOS is complex and involves myriad cell types (both immune and nonimmune) and release of diverse cytokines and chemokines. Unfortunately, current therapies for BOS are of unproven value. A greater understanding of the pathogenic mechanisms operative in BOS are critical to developing novel strategies to treat and prevent this devastating complication.

KEYWORDS

Lung transplantation - allograft rejection - chemokine - cytokines - allorecognition - obliterative bronchiolitis - bronchiolitis obliterans syndrome

REFERENCES

  • 1 Trulock E P. Lung transplantation.  Am J Respir Crit Care Med . 1997;  155 789-818
    CrossrefPubMedGoogle Scholar
  • 2 Arcasoy S M, Kotloff R M. Lung transplantation.  N Engl J Med . 1999;  340 1081-1091
    CrossrefPubMedGoogle Scholar
  • 3 Trulock E. Lung and heart-lung transplantation: overview of results.  Semin Respir Crit Care Med . 2001;  22 479-487
    PubMedGoogle Scholar
  • 4 Hertz M I, Taylor D O, Trulock E P. et al . The registry of the international society for heart and lung transplantation: nineteenth official report-2002.  J Heart Lung Transplant . 2002;  21 950-970
    PubMedGoogle Scholar
  • 5 Estenne M, Hertz M I. Bronchiolitis obliterans after human lung transplantation.  Am J Respir Crit Care Med . 2002;  166 440-444
    CrossrefPubMedGoogle Scholar
  • 6 Sharples L D, McNeil K, Stewart S. et al . Risk factors for bronchiolitis obliterans: a systematic review of recent publications.  J Heart Lung Transplant . 2002;  21 271-281
    CrossrefPubMedGoogle Scholar
  • 7 Yousem S A, Duncan S R, Griffith B P. Interstitial and airspace granulation tissue reactions in lung transplant recipients.  Am J Surg Pathol . 1992;  16 877-884
    PubMedGoogle Scholar
  • 8 Luckraz H, Sharples L, McNeil K. et al . Cytomegalovirus antibody status of donor/recipient does not influence the incidence of bronchiolitis obliterans syndrome in lung transplantation.  J Heart Lung Transplant . 2003;  22 287-291
    CrossrefPubMedGoogle Scholar
  • 9 Heng D, Sharples L D, McNeil K. et al . Bronchiolitis obliterans syndrome: incidence, natural history, prognosis, and risk factors.  J Heart Lung Transplant . 1998;  17 1255-1263
    PubMedGoogle Scholar
  • 10 Chaparro C, Chamberlain D, Maurer J. et al . Bronchiolitis obliterans organizing pneumonia (BOOP) in lung transplant recipients.  Chest . 1996;  110 1150-1154
    PubMedGoogle Scholar
  • 11 Estenne M, Maurer J R, Boehler A. et al . Bronchiolitis obliterans syndrome 2001; an update of the diagnostic criteria.  J Heart Lung Transplant . 2002;  21 297-310
    CrossrefPubMedGoogle Scholar
  • 12 Kelly K, Hertz M I. Obliterative bronchiolitis.  Clin Chest Med . 1997;  18 319-338
    CrossrefPubMedGoogle Scholar
  • 13 Paradis I, Yousem S, Griffith B. Airway obstruction and bronchiolitis obliterans after lung transplantation.  Clin Chest Med . 1993;  14 751-763
    PubMedGoogle Scholar
  • 14 Heng D, Sharples L D, McNeil K. et al . Bronchiolitis obliterans syndrome: incidence, natural history, prognosis, and risk factors.  J Heart Lung Transplant . 1998;  17 1255-1263
    PubMedGoogle Scholar
  • 15 Valentine V G, Robbins R C, Berry G J. et al . Actuarial survival of heart-lung and bilateral sequential lung transplant recipients with obliterative bronchiolitis.  J Heart Lung Transplant . 1996;  15 371-383
    PubMedGoogle Scholar
  • 16 Verleden G. Chronic allograft rejection (obliterative bronchiolitis).  Semin Respir Crit Care Med . 2001;  22 551-557
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 17 Ouwens J P, van der Mark W T, Koeter G H. et al . Bronchiolar airflow impairment after lung transplantation: an early and common manifestation.  J Heart Lung Transplant . 2002;  21 1056-1061
    PubMedGoogle Scholar
  • 18 Tamm M, Sharples L D, Higenbottam T W. et al . Bronchiolitis obliterans syndrome in heart-lung transplantation: surveillance biopsies.  Am J Respir Crit Care Med . 1997;  155 1705-1710
    CrossrefPubMedGoogle Scholar
  • 19 Glanville A, Baldwin J, Burke C. et al . Obliterative bronchiolitis after heart-lung transplantation: Apparent arrest by augmented immunosuppression.  Ann Intern Med . 1987;  107 300-304
    PubMedGoogle Scholar
  • 20 Kesten S, Maidenberg A, Winton T. et al . Treatment of presumed and proven acute rejection following six months of lung transplant survival.  Am J Respir Crit Care Med . 1995;  152(4 Pt 1) 1321-1324
    CrossrefPubMedGoogle Scholar
  • 21 Trulock E P. Management of lung transplant rejection.  Chest . 1993;  103 1566-1576
    PubMedGoogle Scholar
  • 22 Jackson C H, Sharples L D, McNeil K. et al . Acute and chronic onset of bronchiolitis obliterans syndrome (BOS): are they different entities?.  J Heart Lung Transplant . 2002;  21 658-666
    CrossrefPubMedGoogle Scholar
  • 23 Yousem S A. Lymphocytic bronchitis/bronchiolitis in lung allograft recipients.  Am J Surg Pathol . 1993;  17 491-496
    CrossrefPubMedGoogle Scholar
  • 24 Yousem S A, Berry G J, Cagle P T. et al . Revision of the 1990 working formulation for the classification of pulmonary allograft rejection: Lung Rejection Study Group.  J Heart Lung Transplant . 1996;  15(1 Pt 1) 1-15
    PubMedGoogle Scholar
  • 25 Girgis R E, Tu I, Berry G J. et al . Risk factors for the development of obliterative bronchiolitis after lung transplantation.  J Heart Lung Transplant . 1996;  15 1200-1208
    PubMedGoogle Scholar
  • 26 El-Gamel A, Sim E, Hasleton P. et al . Transforming growth factor beta (TGF-beta) and obliterative bronchiolitis following pulmonary transplantation.  J Heart Lung Transplant . 1999;  18 828-837
    PubMedGoogle Scholar
  • 27 Husain A N, Siddiqui M T, Holmes E W. et al . Analysis of risk factors for the development of bronchiolitis obliterans syndrome.  Am J Respir Crit Care Med . 1999;  159 829-833
    CrossrefPubMedGoogle Scholar
  • 28 Abernathy E C, Hruban R H, Baumgartner W A. et al . The two forms of bronchiolitis obliterans in heart-lung transplant recipients.  Hum Pathol . 1991;  22 1102-1110
    CrossrefPubMedGoogle Scholar
  • 29 Milne D S, Gascoigne A D, Ashcroft T. et al . Organizing pneumonia following pulmonary transplantation and the development of obliterative bronchiolitis.  Transplantation . 1994;  57 1757-1762
    PubMedGoogle Scholar
  • 30 Kukafka D S, O'Brien G M, Furukawa S. et al . Surveillance bronchoscopy in lung transplant recipients.  Chest . 1997;  111 377-381
    CrossrefPubMedGoogle Scholar
  • 31 Valentine V G, Taylor D E, Dhillon G S. et al . Success of lung transplantation without surveillance bronchoscopy.  J Heart Lung Transplant . 2002;  21 319-326
    CrossrefPubMedGoogle Scholar
  • 32 Patel S R, Kirby T J, McCarthy P M. et al . Lung transplantation: the Cleveland Clinic experience.  Cleve Clin J Med . 1993;  60 303-319
    PubMedGoogle Scholar
  • 33 Hopkins P M, Aboyoun C L, Chhajed P N. et al . Prospective analysis of 1,235 transbronchial lung biopsies in lung transplant recipients.  J Heart Lung Transplant . 2002;  21 1062-1067
    CrossrefPubMedGoogle Scholar
  • 34 Baz M A, Layish D T, Govert J A. et al . Diagnostic yield of bronchoscopies after isolated lung transplantation.  Chest . 1996;  110 84-88
    CrossrefPubMedGoogle Scholar
  • 35 Sibley R K, Berry G J, Tazelaar H D. et al . The role of transbronchial biopsies in the management of lung transplant recipients.  J Heart Lung Transplant . 1993;  12 308-324
    PubMedGoogle Scholar
  • 36 Kesten S, Chamberlain D, Maurer J. Yield of surveillance transbronchial biopsies performed beyond two years after lung transplantation.  J Heart Lung Transplant . 1996;  15 384-388
    PubMedGoogle Scholar
  • 37 Boehler A, Vogt P, Zollinger A. et al . Prospective study of the value of transbronchial lung biopsy after lung transplantation.  Eur Respir J . 1996;  9 658-662
    CrossrefPubMedGoogle Scholar
  • 38 Estenne M, Van Muylem A, Knoop C. et al . Detection of obliterative bronchiolitis after lung transplantation by indexes of ventilation distribution.  Am J Respir Crit Care Med . 2000;  162(3 Pt 1) 1047-1051
    PubMedGoogle Scholar
  • 39 Nathan S D, Ross D J, Belman M J. et al . Bronchiolitis obliterans in single-lung transplant recipients.  Chest . 1995;  107 967-972
    PubMedGoogle Scholar
  • 40 Kramer M R, Stoehr C, Whang J L. et al . The diagnosis of obliterative bronchiolitis after heart-lung and lung transplantation: low yield of transbronchial lung biopsy.  J Heart Lung Transplant . 1993;  12 675-681
    PubMedGoogle Scholar
  • 41 Chamberlain D, Maurer J, Chaparro C. et al . Evaluation of transbronchial lung biopsy specimens in the diagnosis of bronchiolitis obliterans after lung transplantation.  J Heart Lung Transplant . 1994;  13 963-971
    PubMedGoogle Scholar
  • 42 Sundaresan S, Trulock E P, Mohanakumar T. et al . Prevalence and outcome of bronchiolitis obliterans syndrome after lung transplantation. Washington University Lung Transplant Group.  Ann Thorac Surg . 1995;  60 1341-1347
    CrossrefPubMedGoogle Scholar
  • 43 Cooper J D, Billingham M, Egan T. et al . A working formulation for the standardization of nomenclature and for clinical staging of chronic dysfunction in lung allografts. International Society for Heart and Lung Transplantation.  J Heart Lung Transplant . 1993;  12 713-716
    PubMedGoogle Scholar
  • 44 Chacon R A, Corris P A, Dark J H. et al . Tests of airway function in detecting and monitoring treatment of obliterative bronchiolitis after lung transplantation.  J Heart Lung Transplant . 2000;  19 263-269
    PubMedGoogle Scholar
  • 45 Patterson G M, Wilson S, Whang J L. et al . Physiologic definitions of obliterative bronchiolitis in heart-lung and double lung transplantation: a comparison of the forced expiratory flow between 25% and 75% of the forced vital capacity and forced expiratory volume in one second.  J Heart Lung Transplant . 1996;  15 175-181
    PubMedGoogle Scholar
  • 46 Reynaud-Gaubert M, Thomas P, Badier M. et al . Early detection of airway involvement in obliterative bronchiolitis after lung transplantation: functional and bronchoalveolar lavage cell findings.  Am J Respir Crit Care Med . 2000;  161 1924-1929
    CrossrefPubMedGoogle Scholar
  • 47 Martinez J A, Paradis I L, Dauber J H. et al . Spirometry values in stable lung transplant recipients.  Am J Respir Crit Care Med . 1997;  155 285-290
    PubMedGoogle Scholar
  • 48 Nathan S D, Barnett S D, Wohlrab J. et al . Bronchiolitis obliterans syndrome: utility of the new guidelines in single lung transplant recipients.  J Heart Lung Transplant . 2003;  22 427-432
    PubMedGoogle Scholar
  • 49 Morlion B, Knoop C, Paiva M. et al . Internet-based home monitoring of pulmonary function after lung transplantation.  Am J Respir Crit Care Med . 2002;  165 694-697
    PubMedGoogle Scholar
  • 50 Finkelstein S M, Snyder M, Stibbe C E. et al . Staging of bronchiolitis obliterans syndrome using home spirometry.  Chest . 1999;  116 120-126
    CrossrefPubMedGoogle Scholar
  • 51 Stanbrook M B, Kesten S. Bronchial hyperreactivity after lung transplantation predicts early bronchiolitis obliterans.  Am J Respir Crit Care Med . 1999;  160 2034-2039
    PubMedGoogle Scholar
  • 52 Rajagopalan N, Maurer J, Kesten S. Bronchodilator response at low lung volumes predicts bronchiolitis obliterans in lung transplant recipients.  Chest . 1996;  109 405-407
    PubMedGoogle Scholar
  • 53 Lee E S, Gotway M B, Reddy G P. et al . Early bronchiolitis obliterans following lung transplantation: accuracy of expiratory thin-section CT for diagnosis.  Radiology . 2000;  216 472-477
    PubMedGoogle Scholar
  • 54 Leung A N, Fisher K, Valentine V. et al . Bronchiolitis obliterans after lung transplantation: detection using expiratory HRCT.  Chest . 1998;  113 365-370
    PubMedGoogle Scholar
  • 55 Siegel M J, Bhalla S, Gutierrez F R. et al . Post-lung transplantation bronchiolitis obliterans syndrome: usefulness of expiratory thin-section CT for diagnosis.  Radiology . 2001;  220 455-462
    PubMedGoogle Scholar
  • 56 Bankier A A, Van Muylem A, Knoop C. et al . Bronchiolitis obliterans syndrome in heart-lung transplant recipients: diagnosis with expiratory CT.  Radiology . 2001;  218 533-539
    PubMedGoogle Scholar
  • 57 Medina L S, Siegel M J, Glazer H S. et al . Diagnosis of pulmonary complications associated with lung transplantation in children: value of CT vs histopathologic studies.  AJR Am J Roentgenol . 1994;  162 969-974
    PubMedGoogle Scholar
  • 58 Worthy S A, Park C S, Kim J S. et al . Bronchiolitis obliterans after lung transplantation: high-resolution CT findings in 15 patients.  AJR Am J Roentgenol . 1997;  169 673-677
    PubMedGoogle Scholar
  • 59 Ikonen T, Kivisaari L, Harjula A L. et al . Value of high-resolution computed tomography in routine evaluation of lung transplantation recipients during development of bronchiolitis obliterans syndrome.  J Heart Lung Transplant . 1996;  15 587-595
    PubMedGoogle Scholar
  • 60 Slebos D J, Scholma J, Marike Boezen H. et al . Longitudinal profile of bronchoalveolar lavage cell characteristics in patients with a good outcome after lung transplantation.  Am J Respir Crit Care Med . 2002;  165 501-507
    PubMedGoogle Scholar
  • 61 Zheng L, Walters E H, Ward C. et al . Airway neutrophilia in stable and bronchiolitis obliterans syndrome patients following lung transplantation.  Thorax . 2000;  55 53-59
    CrossrefPubMedGoogle Scholar
  • 62 DiGiovine B, Lynch III P J, Martinez F J. et al . Bronchoalveolar lavage neutrophilia is associated with obliterative bronchiolitis after lung transplantation: role of IL-8.  J Immunol . 1996;  157 4194-4202
    PubMedGoogle Scholar
  • 63 Reynaud-Gaubert M, Marin V, Thirion X. et al . Upregulation of chemokines in bronchoalveolar lavage fluid as a predictive marker of posttransplant airway obliteration.  J Heart Lung Transplant . 2002;  21 721-730
    CrossrefPubMedGoogle Scholar
  • 64 Belperio J A, Burdick M D, Keane M P. et al . The role of the CC chemokine, RANTES, in acute lung allograft rejection.  J Immunol . 2000;  165 461-472
    PubMedGoogle Scholar
  • 65 Belperio J A, Keane M P, Burdick M D. et al . Critical role for the chemokine MCP-1/CCR2 in the pathogenesis of bronchiolitis obliterans syndrome.  J Clin Invest . 2001;  108 547-556
    CrossrefPubMedGoogle Scholar
  • 66 Belperio J A, DiGiovine B, Keane M P. et al . Interleukin-1 receptor antagonist as a biomarker for bronchiolitis obliterans syndrome in lung transplant recipients.  Transplantation . 2002;  73 591-599
    CrossrefPubMedGoogle Scholar
  • 67 Belperio J A, Keane M P, Burdick M D. et al . Critical role for CXCR3 chemokine biology in the pathogenesis of bronchiolitis obliterans syndrome.  J Immunol . 2002;  169 1037-1049
    PubMedGoogle Scholar
  • 68 Scholma J, Slebos D J, Boezen H M. et al . Eosinophilic granulocytes and interleukin-6 level in bronchoalveolar lavage fluid are associated with the development of obliterative bronchiolitis after lung transplantation.  Am J Respir Crit Care Med . 2000;  162 2221-2225
    CrossrefPubMedGoogle Scholar
  • 69 Gabbay E, Walters E H, Orsida B. et al . Post-lung transplant bronchiolitis obliterans syndrome (BOS) is characterized by increased exhaled nitric oxide levels and epithelial inducible nitric oxide synthase.  Am J Respir Crit Care Med . 2000;  162 2182-2187
    PubMedGoogle Scholar
  • 70 Gabbay E, Fisher A J, Small T. et al . Exhaled single-breath nitric oxide measurements are reproducible, repeatable and reflect levels of nitric oxide found in the lower airways.  Eur Respir J . 1998;  11 467-472
    CrossrefPubMedGoogle Scholar
  • 71 Verleden G M, Dupont L, Lamont J. et al . Is there a role for measuring exhaled nitric oxide in lung transplant recipients with chronic rejection?.  J Heart Lung Transplant . 1998;  17 231-232
    PubMedGoogle Scholar
  • 72 Brugiere O, Pessione F, Thabut G. et al . Bronchiolitis obliterans syndrome after single-lung transplantation: impact of time to onset on functional pattern and survival.  Chest . 2002;  121 1883-1889
    CrossrefPubMedGoogle Scholar
  • 73 Snell G I, Esmore D S, Williams T J. Cytolytic therapy for the bronchiolitis obliterans syndrome complicating lung transplantation Chest .  1996;  109 874-878
    CrossrefPubMedGoogle Scholar
  • 74 Reinsmoen N L, Bolman R M, Savik K. et al . Are multiple immunopathogenetic events occurring during the development of obliterative bronchiolitis and acute rejection?.  Transplantation . 1993;  55 1040-1044
    PubMedGoogle Scholar
  • 75 Kroshus T J, Kshettry V R, Savik K. et al . Risk factors for the development of bronchiolitis obliterans syndrome after lung transplantation.  J Thorac Cardiovasc Surg . 1997;  114 195-202
    CrossrefPubMedGoogle Scholar
  • 76 Smith M A, Sundaresan S, Mohanakumar T. et al . Effect of development of antibodies to HLA and cytomegalovirus mismatch on lung transplantation survival and development of bronchiolitis obliterans syndrome.  J Thorac Cardiovasc Surg . 1998;  116 812-820
    CrossrefPubMedGoogle Scholar
  • 77 Bando K, Paradis I L, Komatsu K. et al . Analysis of time-dependent risks for infection, rejection, and death after pulmonary transplantation.  J Thorac Cardiovasc Surg . 1995;  109 49-57
    PubMedGoogle Scholar
  • 78 Keller C A, Cagle P T, Brown R W. et al . Bronchiolitis obliterans in recipients of single, double, and heart-lung transplantation.  Chest . 1995;  107 973-980
    CrossrefPubMedGoogle Scholar
  • 79 Bando K, Paradis I L, Similo S. et al . Obliterative bronchiolitis after lung and heart-lung transplantation: an analysis of risk factors and management.  J Thorac Cardiovasc Surg . 1995;  110 4-14
    CrossrefPubMedGoogle Scholar
  • 80 Duncan S R, Paradis I L, Yousem S A. et al . Sequelae of cytomegalovirus pulmonary infections in lung allograft recipients.  Am Rev Respir Dis . 1992;  146 1419-1425
    PubMedGoogle Scholar
  • 81 Speich R, Thurnheer R, Gaspert A. et al . Efficacy and cost effectiveness of oral ganciclovir in the prevention of cytomegalovirus disease after lung transplantation.  Transplantation . 1999;  67 315-320
    CrossrefPubMedGoogle Scholar
  • 82 Soghikian M V, Valentine V G, Berry G J. et al . Impact of ganciclovir prophylaxis on heart-lung and lung transplant recipients.  J Heart Lung Transplant . 1996;  15 881-887
    PubMedGoogle Scholar
  • 83 Duncan S R, Paradis I L, Dauber J H. et al . Ganciclovir prophylaxis for cytomegalovirus infections in pulmonary allograft recipients.  Am Rev Respir Dis . 1992;  146(5 Pt 1) 1213-1215
    PubMedGoogle Scholar
  • 84 Kruger R M, Shannon W D, Arens M Q. et al . The impact of ganciclovir-resistant cytomegalovirus infection after lung transplantation.  Transplantation . 1999;  68 1272-1279
    CrossrefPubMedGoogle Scholar
  • 85 Taylor P M, Rose M L, Yacoub M H. Expression of MHC antigens in normal human lungs and transplanted lungs with obliterative bronchiolitis.  Transplantation . 1989;  48 506-510
    PubMedGoogle Scholar
  • 86 Beck S, Barrell B G. Human cytomegalovirus encodes a glycoprotein homologous to MHC class-I antigens.  Nature . 1988;  331 269-272
    CrossrefPubMedGoogle Scholar
  • 87 Arbustini E, Morbini P, Grasso M. et al . Human cytomegalovirus early infection, acute rejection, and major histocompatibility class II expression in transplanted lung: molecular, immunocytochemical, and histopathologic investigations.  Transplantation . 1996;  61 418-427
    PubMedGoogle Scholar
  • 88 Theise N D, Haber M M, Grimes M M. Detection of cytomegalovirus in lung allografts: comparison of histologic and immunohistochemical findings.  Am J Clin Pathol . 1991;  96 762-766
    PubMedGoogle Scholar
  • 89 Opelz G, Mytilineos J, Scherer S. et al . Analysis of HLA-DR matching in DNA-typed cadaver kidney transplants.  Transplantation . 1993;  55 782-785
    PubMedGoogle Scholar
  • 90 Opelz G, Wujciak T. The influence of HLA compatibility on graft survival after heart transplantation. The Collaborative Transplant Study.  N Engl J Med . 1994;  330 816-819
    CrossrefPubMedGoogle Scholar
  • 91 Morris P J. HLA matching and cardiac transplantation.  N Engl J Med . 1994;  330 857-858
    CrossrefPubMedGoogle Scholar
  • 92 Iwaki Y, Yoshida Y, Griffith B. The HLA matching effect in lung transplantation.  Transplantation . 1993;  56 1528-1529
    PubMedGoogle Scholar
  • 93 Keogh A, Kaan A, Doran T. et al . HLA mismatching and outcome in heart, heart-lung, and single lung transplantation.  J Heart Lung Transplant . 1995;  14 444-451
    PubMedGoogle Scholar
  • 94 Bando K, Paradis I L, Keenan R J. et al . Comparison of outcomes after single and bilateral lung transplantation for obstructive lung disease.  J Heart Lung Transplant . 1995;  14 692-698
    PubMedGoogle Scholar
  • 95 Harjula A, Baldwin J C, Starnes V A. et al . Proper donor selection for heart-lung transplantation: the Stanford experience.  J Thorac Cardiovasc Surg . 1987;  94 874-880
    PubMedGoogle Scholar
  • 96 Wisser W, Wekerle T, Zlabinger G. et al . Influence of human leukocyte antigen matching on long-term outcome after lung transplantation.  J Heart Lung Transplant . 1996;  15 1209-1216
    PubMedGoogle Scholar
  • 97 Quantz M A, Bennett L E, Meyer D M. et al . Does human leukocyte antigen matching influence the outcome of lung transplantation?.  <~>An analysis of 3,549 lung transplantations. J Heart Lung Transplant . 2000;  19 473-479
    CrossrefPubMedGoogle Scholar
  • 98 King R C, Binns O A, Rodriguez F. et al . Reperfusion injury significantly impacts clinical outcome after pulmonary transplantation.  Ann Thorac Surg . 2000;  69 1681-1685
    CrossrefPubMedGoogle Scholar
  • 99 Sleiman C, Mal H, Fournier M. et al . Pulmonary reimplantation response in single-lung transplantation.  Eur Respir J . 1995;  8 5-9
    CrossrefPubMedGoogle Scholar
  • 100 Fisher A J, Wardle J, Dark J H. et al . Nonimmune acute graft injury after lung transplantation and the risk of subsequent bronchiolitis obliterans syndrome (BOS).  J Heart Lung Transplant . 2002;  21 1206-1212
    CrossrefPubMedGoogle Scholar
  • 101 Christie J D, Bavaria J E, Palevsky H I. et al . Primary graft failure following lung transplantation.  Chest . 1998;  114 51-60
    CrossrefPubMedGoogle Scholar
  • 102 Waddell T K, Gorczynski R M, DeCampos K N. et al . Major histocompatibility complex expression and lung ischemia-reperfusion in rats.  Ann Thorac Surg . 1996;  62 866-872
    CrossrefPubMedGoogle Scholar
  • 103 Fisher A J, Donnelly S C, Hirani N. et al . Elevated levels of interleukin-8 in donor lungs is associated with early graft failure after lung transplantation.  Am J Respir Crit Care Med . 2001;  163 259-265
    CrossrefPubMedGoogle Scholar
  • 104 Fisher A J, Donnelly S C, Hirani N. et al . Enhanced pulmonary inflammation in organ donors following fatal nontraumatic brain injury.  Lancet . 1999;  353 1412-1413
    CrossrefPubMedGoogle Scholar
  • 105 Takada M, Nadeau K C, Hancock W W. et al . Effects of explosive brain death on cytokine activation of peripheral organs in the rat.  Transplantation . 1998;  65 1533-1542
    CrossrefPubMedGoogle Scholar
  • 106 Clark S C, Sudarshan C, Khanna R. et al . Controlled reperfusion and pentoxifylline modulate reperfusion injury after single lung transplantation.  J Thorac Cardiovasc Surg . 1998;  115 1335-1341
    PubMedGoogle Scholar
  • 107 Fiser S M, Kron I L, Long S M. et al . Influence of graft ischemic time on outcomes following lung transplantation.  J Heart Lung Transplant . 2001;  20 1291-1296
    PubMedGoogle Scholar
  • 108 Novick R J, Bennett L E, Meyer D M. et al . Influence of graft ischemic time and donor age on survival after lung transplantation.  J Heart Lung Transplant . 1999;  18 425-431
    PubMedGoogle Scholar
  • 109 Ueno T, Snell G I, Williams T J. et al . Impact of graft ischemic time on outcomes after bilateral sequential single-lung transplantation.  Ann Thorac Surg . 1999;  67 1577-1582
    CrossrefPubMedGoogle Scholar
  • 110 Kshettry V R, Kroshus T J, Burdine J. et al . Does donor organ ischemia over four hours affect long-term survival after lung transplantation?.  J Heart Lung Transplant . 1996;  15 169-174
    PubMedGoogle Scholar
  • 111 Gammie J S, Stukus D R, Pham S M. et al . Effect of ischemic time on survival in clinical lung transplantation.  Ann Thorac Surg . 1999;  68 2015-2020
    CrossrefPubMedGoogle Scholar
  • 112 Snell G I, Rabinov M, Griffiths A. et al . Pulmonary allograft ischemic time: an important predictor of survival after lung transplantation.  J Heart Lung Transplant . 1996;  15 160-168
    PubMedGoogle Scholar
  • 113 Dusmet M, Maurer J, Winton T. et al . Methotrexate can halt the progression of bronchiolitis obliterans syndrome in lung transplant recipients.  J Heart Lung Transplant . 1996;  15 948-954
    PubMedGoogle Scholar
  • 114 Hosenpud J D, Bennett L E, Keck B M. et al . Effect of diagnosis on survival benefit of lung transplantation for end-stage lung disease Lancet .  1997;  351(9095) 24-27
    PubMedGoogle Scholar
  • 115 Glanville A R, Marshman D, Keogh A. et al . Outcome in paired recipients of single lung transplants from the same donor.  J Heart Lung Transplant . 1995;  14 878-882
    PubMedGoogle Scholar
  • 116 Winton T L, Miller J D, deHoyos A. et al . Graft function, airway healing, rejection, and survival in pulmonary transplantation are not affected by graft ischemia in excess of 5 hours.  Transplant Proc . 1993;  25(1 Pt 2) 1649-1650
    PubMedGoogle Scholar
  • 117 Marshall R, Bellingan G, Laurent G. The acute respiratory distress syndrome: fibrosis in the fast lane.  Thorax . 1998;  53 815-817
    PubMedGoogle Scholar
  • 118 Boehler A, Chamberlain D, Kesten S. et al . Lymphocytic airway infiltration as a precursor to fibrous obliteration in a rat model of bronchiolitis obliterans.  Transplantation . 1997;  64 311-317
    PubMedGoogle Scholar
  • 119 Hohlfeld J, Niedermeyer J, Hamm H. et al . Seasonal onset of bronchiolitis obliterans syndrome in lung transplant recipients.  J Heart Lung Transplant . 1996;  15 888-894
    PubMedGoogle Scholar
  • 120 Billings J L, Hertz M I, Savik K. et al . Respiratory viruses and chronic rejection in lung transplant recipients.  J Heart Lung Transplant . 2002;  21 559-566
    CrossrefPubMedGoogle Scholar
  • 121 Winter J B, Gouw A SH, Groen M. et al . Respiratory viral infections aggravate airway damage caused by chronic rejection in rat lung allografts.  Transplantation . 1994;  57 418-422
    CrossrefPubMedGoogle Scholar
  • 122 Norgaard M A, Andersen C B, Pettersson G. Does bronchial artery revascularization influence results concerning bronchiolitis obliterans syndrome and/or obliterative bronchiolitis after lung transplantation?.  Eur J Cardiothorac Surg . 1998;  14 311-318
    PubMedGoogle Scholar
  • 123 Haider Y, Yonan N, Mogulkoc N. et al . Bronchiolitis obliterans syndrome in single lung transplant recipients: patients with emphysema versus patients with idiopathic pulmonary fibrosis.  J Heart Lung Transplant . 2002;  21 327-333
    CrossrefPubMedGoogle Scholar
  • 124 Sundaresan S, Mohanakumar T, Smith M A. et al . HLA-A locus mismatches and development of antibodies to HLA after lung transplantation correlate with the development of bronchiolitis obliterans syndrome.  Transplantation . 1998;  65 648-653
    CrossrefPubMedGoogle Scholar
  • 125 Wiebe K, Harringer W, Wahlers T. et al . ATG induction therapy and the incidence of bronchiolitis obliterans after lung transplantation: does it make a difference?.  Transplant Proc . 1998;  30 1517-1518
    CrossrefPubMedGoogle Scholar
  • 126 Halloran P F, Homik J, Goes N. et al . The “injury response”: a concept linking nonspecific injury, acute rejection, and long-term transplant outcomes.  Transplant Proc . 1997;  29 79-81
    CrossrefPubMedGoogle Scholar
  • 127 Neuringer I P, Mannon R B, Coffman T M. et al . Immune cells in a mouse airway model of obliterative bronchiolitis.  Am J Respir Cell Mol Biol . 1998;  19 379-386
    PubMedGoogle Scholar
  • 128 Holland V A, Cagle P T, Windsor N T. et al . Lymphocyte subset populations in bronchiolitis obliterans after heart-lung transplantation.  Transplantation . 1990;  50 955-959
    PubMedGoogle Scholar
  • 129 Ross D J, Marchevsky A, Kramer M. et al . “Refractoriness” of airflow obstruction associated with isolated lymphocytic bronchiolitis/bronchitis in pulmonary allografts.  J Heart Lung Transplant . 1997;  16 832-838
    PubMedGoogle Scholar
  • 130 Boehler A, Bai X H, Liu M. et al . Upregulation of T-helper 1 cytokines and chemokine expression in post-transplant airway obliteration.  Am J Respir Crit Care Med . 1999;  159 1910-1917
    PubMedGoogle Scholar
  • 131 Magnan A, Mege J L, Escallier J C. et al . Balance between alveolar macrophage IL-6 and TGF-beta in lung-transplant recipients. Marseille and Montreal Lung Transplantation Group.  Am J Respir Crit Care Med . 1996;  153(4 Pt 1) 1431-1436
    PubMedGoogle Scholar
  • 132 Magnan A, Mege J L, Reynaud M. et al . Monitoring of alveolar macrophage production of tumor necrosis factor-alpha and interleukin-6 in lung transplant recipients. Marseille and Montreal Lung Transplantation Group.  Am J Respir Crit Care Med . 1994;  150 684-689
    PubMedGoogle Scholar
  • 133 Riise G C, Andersson B A, Kjellstrom C. et al . Persistent high BAL fluid granulocyte activation marker levels as early indicators of bronchiolitis obliterans after lung transplant.  Eur Respir J . 1999;  14 1123-1130
    CrossrefPubMedGoogle Scholar
  • 134 Riise G C, Andersson B A, Kjellstrom C. et al . Persistent high BAL fluid granulocyte activation marker levels as early indicators of bronchiolitis obliterans after lung transplant.  Eur Respir J . 1999;  14 1123-1130
    CrossrefPubMedGoogle Scholar
  • 135 Borger P, Kauffman H F, Scholma J. et al . Human allogeneic CD2+ lymphocytes activate airway-derived epithelial cells to produce interleukin-6 and interleukin-8: possible role for the epithelium in chronic allograft rejection.  J Heart Lung Transplant . 2002;  21 567-575
    PubMedGoogle Scholar
  • 136 Mason N A, Springall D R, Pomerance A. et al . Expression of inducible nitric oxide synthase and formation of peroxynitrite in posttransplant obliterative bronchiolitis.  J Heart Lung Transplant . 1998;  17 710-714
    PubMedGoogle Scholar
  • 137 Mauck K A, Hosenpud J D. The bronchial epithelium: a potential allogeneic target for chronic rejection after lung transplantation.  J Heart Lung Transplant . 1996;  15 709-714
    PubMedGoogle Scholar
  • 138 Hertz M I, Henke C A, Nakhleh R E. et al . Obliterative bronchiolitis after lung transplantation: a fibroproliferative disorder associated with platelet-derived growth factor.  Proc Natl Acad Sci USA . 1992;  89 10385-10389
    CrossrefPubMedGoogle Scholar
  • 139 Romanska H M, Ikonen T S, Bishop A E. et al . Up-regulation of inducible nitric oxide synthase in fibroblasts parallels the onset and progression of fibrosis in an experimental model of posttransplant obliterative airway disease.  J Pathol . 2000;  191 71-77
    PubMedGoogle Scholar
  • 140 Jonosono M, Fang K C, Keith F M. et al . Measurement of fibroblast proliferative activity in bronchoalveolar lavage fluid in the analysis of obliterative bronchiolitis among lung transplant recipients.  J Heart Lung Transplant . 1999;  18 972-985
    PubMedGoogle Scholar
  • 141 Borger P, Kauffman H F, Timmerman J A. et al . Cyclosporine, FK506, mycophenolate mofetil, and prednisolone differentially modulate cytokine gene expression in human airway-derived epithelial cells.  Transplantation . 2000;  69 1408-1413
    PubMedGoogle Scholar
  • 142 Klein J, Sato A. The HLA system. First of two parts.  N Engl J Med . 2000;  343 702-709
    CrossrefPubMedGoogle Scholar
  • 143 Klein J, Sato A. The HLA system. Second of two parts.  N Engl J Med . 2000;  343 782-786
    CrossrefPubMedGoogle Scholar
  • 144 Rogers N J, Lechler R I. Allorecognition.  Am J Transplant . 2001;  1 97-102
    PubMedGoogle Scholar
  • 145 Benichou G. Direct and indirect antigen recognition: the pathways to allograft immune rejection.  Front Biosci . 1999;  4 D476-D480
    PubMedGoogle Scholar
  • 146 Womer K L, Lee R S, Madsen J C. et al . Tolerance and chronic rejection.  Philos Trans R Soc Lond B Biol Sci . 2001;  356 727-738
    PubMedGoogle Scholar
  • 147 Womer K L, Sayegh M H, Auchincloss Jr H. Involvement of the direct and indirect pathways of allorecognition in tolerance induction.  Philos Trans R Soc Lond B Biol Sci . 2001;  356 639-647
    PubMedGoogle Scholar
  • 148 Parham P, Clayberger C, Zorn S L. et al . Inhibition of alloreactive cytotoxic T lymphocytes by peptides from the alpha 2 domain of HLA-A2.  Nature . 1987;  325 625-628
    CrossrefPubMedGoogle Scholar
  • 149 Chicz R M, Urban R G, Lane W S. et al . Predominant naturally processed peptides bound to HLA-DR1 are derived from MHC-related molecules and are heterogeneous in size.  Nature . 1992;  358 764-768
    CrossrefPubMedGoogle Scholar
  • 150 Shoskes D A, Wood K J. Indirect presentation of MHC antigens in transplantation.  Immunol Today . 1994;  15 32-38
    CrossrefPubMedGoogle Scholar
  • 151 Lechler R I, Lombardi G, Batchelor J R. et al . The molecular basis of alloreactivity.  Immunol Today . 1990;  11 83-88
    CrossrefPubMedGoogle Scholar
  • 152 Sayegh M H, Turka L A. The role of T-cell costimulatory activation pathways in transplant rejection.  N Engl J Med . 1998;  338 1813-1821
    CrossrefPubMedGoogle Scholar
  • 153 Hayry P, von Willebrand E, Parthenais E. et al . The inflammatory mechanisms of allograft rejection.  Immunol Rev . 1984;  77 85-142
    PubMedGoogle Scholar
  • 154 Liu Z, Braunstein N S, Suciu-Foca N. T cell recognition of allopeptides in context of syngeneic MHC.  J Immunol . 1992;  148 35-40
    PubMedGoogle Scholar
  • 155 Valujskikh A, Matesic D, Gilliam A. et al . T cells reactive to a single immunodominant self-restricted allopeptide induce skin graft rejection in mice.  J Clin Invest . 1998;  101 1398-1407
    PubMedGoogle Scholar
  • 156 Fangmann J, Dalchau R, Sawyer G J. et al . T cell recognition of donor major histocompatibility complex class I peptides during allograft rejection.  Eur J Immunol . 1992;  22 1525-1530
    PubMedGoogle Scholar
  • 157 Benichou G, Takizawa P A, Olson C A. et al . Donor major histocompatibility complex (MHC) peptides are presented by recipient MHC molecules during graft rejection.  J Exp Med . 1992;  175 305-308
    CrossrefPubMedGoogle Scholar
  • 158 Lo D, Burkly L C, Flavell R A. et al . Tolerance in transgenic mice expressing class II major histocompatibility complex on pancreatic acinar cells.  J Exp Med . 1989;  170 87-104
    CrossrefPubMedGoogle Scholar
  • 159 Ciubotariu R, Liu Z, Colovai A I. et al . Persistent allopeptide reactivity and epitope spreading in chronic rejection of organ allografts.  J Clin Invest . 1998;  101 398-405
    PubMedGoogle Scholar
  • 160 Vella J P, Spadafora-Ferreira M, Murphy B. et al . Indirect allorecognition of major histocompatibility complex allopeptides in human renal transplant recipients with chronic graft dysfunction.  Transplantation . 1997;  64 795-800
    PubMedGoogle Scholar
  • 161 Gimmi C D, Freeman G J, Gribben J G. et al . Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation.  Proc Natl Acad Sci USA . 1993;  90 6586-6590
    PubMedGoogle Scholar
  • 162 Noel P J, Boise L H, Green J M. et al . CD28 costimulation prevents cell death during primary T cell activation.  J Immunol . 1996;  157 636-642
    PubMedGoogle Scholar
  • 163 June C H, Bluestone J A, Nadler L M. et al . The B7 and CD28 receptor families.  Immunol Today . 1994;  15 321-331
    CrossrefPubMedGoogle Scholar
  • 164 Walunas T L, Bakker C Y, Bluestone J A. CTLA-4 ligation blocks CD28-dependent T cell activation.  J Exp Med . 1996;  183 2541-2550
    CrossrefPubMedGoogle Scholar
  • 165 Guo Y, Wu Y, Shinde S. et al . Identification of a costimulatory molecule rapidly induced by CD40L as CD44H.  J Exp Med . 1996;  184 955-961
    CrossrefPubMedGoogle Scholar
  • 166 Rumbley C A, Silver S J, Phillips S M. Dependence of murine obstructive airway disease on CD40 ligand.  Transplantation . 2001;  72 1616-1625
    PubMedGoogle Scholar
  • 167 Tikkanen J M, Lemstrom K B, Koskinen P K. Blockade of CD28/B7-2 costimulation inhibits experimental obliterative bronchiolitis in rat tracheal allografts: suppression of helper T cell type1-dominated immune response.  Am J Respir Crit Care Med . 2002;  165 724-729
    PubMedGoogle Scholar
  • 168 Dinarello C A. Biologic basis for interleukin-1 in disease.  Blood . 1996;  87 2095-2147
    PubMedGoogle Scholar
  • 169 Hu S, Chao C C, Ehrlich L C. et al . Inhibition of microglial cell RANTES production by IL-10 and TGF-beta.  J Leukoc Biol . 1999;  65 815-821
    PubMedGoogle Scholar
  • 170 Bejarano M T, de Waal Malefyt R, Abrams J S. et al . Interleukin-10 inhibits allogeneic proliferative and cytotoxic T cell responses generated in primary mixed lymphocyte cultures.  Int Immunol . 1992;  4 1389-1397
    PubMedGoogle Scholar
  • 171 Lowry R P, Konieczny B, Alexander D. et al . Interleukin-10 eliminates anti-CD3 monoclonal antibody-induced mortality and prolongs heart allograft survival in inbred mice.  Transplant Proc . 1995;  27 392-394
    PubMedGoogle Scholar
  • 172 Boehler A, Chamberlain D, Xing Z. et al . Adenovirus-mediated interleukin-10 gene transfer inhibits post-transplant fibrous airway obliteration in an animal model of bronchiolitis obliterans.  Hum Gene Ther . 1998;  9 541-551
    PubMedGoogle Scholar
  • 173 Raisanen-Sokolowski A, Mottram P L, Glysing-Jensen T. et al . Heart transplants in interferon-gamma, interleukin 4, and interleukin 10 knockout mice: recipient environment alters graft rejection.  J Clin Invest . 1997;  100 2449-2456
    PubMedGoogle Scholar
  • 174 Penttinen R P, Kobayashi S, Bornstein P. Transforming growth factor beta increases mRNA for matrix proteins both in the presence and in the absence of changes in mRNA stability.  Proc Natl Acad Sci USA . 1988;  85 1105-1108
    PubMedGoogle Scholar
  • 175 Roberts A B, Sporn M B, Assoian R K. et al . Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro.  Proc Natl Acad Sci USA . 1986;  83 4167-4171
    PubMedGoogle Scholar
  • 176 Elssner A, Jaumann F, Dobmann S. et al . Elevated levels of interleukin-8 and transforming growth factor-beta in bronchoalveolar lavage fluid from patients with bronchiolitis obliterans syndrome: proinflammatory role of bronchial epithelial cells. Munich Lung Transplant Group.  Transplantation . 2000;  70 362-367
    PubMedGoogle Scholar
  • 177 Liu M, Suga M, Maclean A A. et al . Soluble transforming growth factor-beta type III receptor gene transfection inhibits fibrous airway obliteration in a rat model of bronchiolitis obliterans.  Am J Respir Crit Care Med . 2002;  165 419-423
    PubMedGoogle Scholar
  • 178 Beutler B A. The role of tumor necrosis factor in health and disease.  J Rheumatol . 1999;  26 (suppl 57) S16-S21
    PubMedGoogle Scholar
  • 179 Ostensen M E, Thiele D L, Lipsky P E. Tumor necrosis factor-alpha enhances cytolytic activity of human natural killer cells.  J Immunol . 1987;  138 4185-4191
    PubMedGoogle Scholar
  • 180 Piguet P F, Collart M A, Grau G E. et al . Tumor necrosis factor/cachectin plays a key role in bleomycin-induced pneumopathy and fibrosis.  J Exp Med . 1989;  170 655-663
    CrossrefPubMedGoogle Scholar
  • 181 He Y, Liu W. The preliminary research on the relationship between TNF- and egg-induced granuloma and hepatic fibrosis of schistosomiasis japonica.  J Tongji Med Univ . 1996;  16 205-208
    PubMedGoogle Scholar
  • 182 Hayashi M, Martinez O M, Garcia-Kennedy R. et al . Expression of cytokines and immune mediators during chronic liver allograft rejection.  Transplantation . 1995;  60 1533-1538
    PubMedGoogle Scholar
  • 183 Noronha I L, Eberlein-Gonska M, Hartley B. et al . In situ expression of tumor necrosis factor-alpha, interferon-gamma, and interleukin-2 receptors in renal allograft biopsies.  Transplantation . 1992;  54 1017-1024
    PubMedGoogle Scholar
  • 184 Aris R M, Walsh S, Chalermskulrat W. et al . Growth factor upregulation during obliterative bronchiolitis in the mouse model.  Am J Respir Crit Care Med . 2002;  166 417-422
    CrossrefPubMedGoogle Scholar
  • 185 Smith C R, Jaramillo A, Lu K C. et al . Prevention of obliterative airway disease in HLA-A2-transgenic tracheal allografts by neutralization of tumor necrosis factor.  Transplantation . 2001;  72 1512-1518
    PubMedGoogle Scholar
  • 186 Cambrey A D, Kwon O J, Gray A J. et al . Insulin-like growth factor I is a major fibroblast mitogen produced by primary cultures of human airway epithelial cells.  Clin Sci (Lond) . 1995;  89 611-617
    PubMedGoogle Scholar
  • 187 Goldstein R H, Poliks C F, Pilch P F. et al . Stimulation of collagen formation by insulin and insulin-like growth factor I in cultures of human lung fibroblasts.  Endocrinology . 1989;  124 964-970
    CrossrefPubMedGoogle Scholar
  • 188 Rom W N, Basset P, Fells G A. et al . Alveolar macrophages release an insulin-like growth factor I-type molecule.  J Clin Invest . 1988;  82 1685-1693
    PubMedGoogle Scholar
  • 189 Homma S, Nagaoka I, Abe H. et al . Localization of platelet-derived growth factor and insulin-like growth factor I in the fibrotic lung.  Am J Respir Crit Care Med . 1995;  152(6 Pt 1) 2084-2089
    PubMedGoogle Scholar
  • 190 Jones J I, Clemmons D R. Insulin-like growth factors and their binding proteins: biological actions.  Endocr Rev . 1995;  16 3-34
    CrossrefPubMedGoogle Scholar
  • 191 Charpin J M, Stern M, Grenet D. et al . Insulinlike growth factor-1 in lung transplants with obliterative bronchiolitis.  Am J Respir Crit Care Med . 2000;  161 1991-1998
    CrossrefPubMedGoogle Scholar
  • 192 Ross R, Raines E W, Bowen-Pope D F. The biology of platelet-derived growth factor.  Cell . 1986;  46 155-169
    CrossrefPubMedGoogle Scholar
  • 193 Williams L T. Signal transduction by the platelet-derived growth factor receptor.  Science . 1989;  243 1564-1570
    PubMedGoogle Scholar
  • 194 Heldin C H, Westermark B. Platelet-derived growth factor: three isoforms and two receptor types.  Trends Genet . 1989;  5 108-111
    CrossrefPubMedGoogle Scholar
  • 195 Kallio E A, Koskinen P K, Aavik E. et al . Role of platelet-derived growth factor in obliterative bronchiolitis (chronic rejection) in the rat.  Am J Respir Crit Care Med . 1999;  160 1324-1332
    CrossrefPubMedGoogle Scholar
  • 196 Rollins B J. Chemokines.  Blood . 1997;  90 909-928
    PubMedGoogle Scholar
  • 197 Luster A D. Review articles: mechanisms of disease: chemokines-chemotactic cytokines that mediate inflammation.  N Engl J Med . 1998;  338 436-445
    CrossrefPubMedGoogle Scholar
  • 198 Strieter R M, Kunkel S L. Chemokines and the lung. In: Crystal R, West J, Weibel E, et al, eds. Lung: Scientific Foundations 2nd ed. New York: Raven 1997: 155-186
    Google Scholar
  • 199 Riise G C, Williams A, Kjellstrom C. et al . Bronchiolitis obliterans syndrome in lung transplant recipients is associated with increased neutrophil activity and decreased antioxidant status in the lung.  Eur Respir J . 1998;  12 82-88
    CrossrefPubMedGoogle Scholar
  • 200 Elssner A, Jaumann F, Dobmann S. et al . Elevated levels of interleukin-8 and transforming growth factor-beta in bronchoalveolar lavage fluid from patients with bronchiolitis obliterans syndrome: proinflammatory role of bronchial epithelial cells. Munich Lung Transplant Group.  Transplantation . 2000;  70 362-367
    PubMedGoogle Scholar
  • 201 Elssner A, Vogelmeier C. The role of neutrophils in the pathogenesis of obliterative bronchiolitis after lung transplantation.  Transpl Infect Dis . 2001;  3 168-176
    CrossrefPubMedGoogle Scholar
  • 202 De Perrot M, Sekine Y, Fischer S. et al . Interleukin-8 release during early reperfusion predicts graft function in human lung transplantation.  Am J Respir Crit Care Med . 2002;  165 211-215
    CrossrefPubMedGoogle Scholar
  • 203 Uvama T, Winter J B, Groen G. et al . Late airway changes caused by chronic rejection in rat lung allografts.  Transplantation . 1992;  54 809-812
    PubMedGoogle Scholar
  • 204 Uyama T, Sakiyama S, Fukumoto T. et al . Graft-infiltrating cells in rat lung allograft with late airway damage.  Transplant Proc . 1995;  27 2118-2119
    PubMedGoogle Scholar
  • 205 Matsumura Y, Marchevsky A, Zuo X J. et al . Assessment of pathological changes associated with chronic allograft rejection and tolerance in two experimental models of rat lung transplantation.  Transplantation . 1995;  59 1509-1517
    PubMedGoogle Scholar
  • 206 Tazelaar H D, Prop J, Nieuwenhuis P. et al . Airway pathology in the transplanted rat lung.  Transplantation . 1988;  45 864-869
    CrossrefPubMedGoogle Scholar
  • 207 Hertz M I, Jessurun J, King M B. et al . Reproduction of the obliterative bronchiolitis lesion after heterotopic transplantation of mouse airways.  Am J Pathol . 1993;  142 1945-1951
    PubMedGoogle Scholar
  • 208 Suga M, Maclean A A, Keshavjee S. et al . RANTES plays an important role in the evolution of allograft transplant-induced fibrous airway obliteration.  Am J Respir Crit Care Med . 2000;  162 1940-1948
    PubMedGoogle Scholar
  • 209 Gao W, Topham P S, King J A. et al . Targeting of the chemokine receptor CCR1 suppresses development of acute and chronic cardiac allograft rejection.  J Clin Invest . 2000;  105 35-44
    PubMedGoogle Scholar
  • 210 Carr M W, Roth S J, Luther E. et al . Monocyte chemoattractant protein 1 acts as a T-lymphocyte chemoattractant.  Proc Natl Acad Sci USA . 1994;  91 3652-3656
    PubMedGoogle Scholar
  • 211 Taub D D, Proost P, Murphy W J. et al . Monocyte chemotactic protein-1 (MCP-1), -2, and -3 are chemotactic for human T lymphocytes.  J Clin Invest . 1995;  95 1370-1376
    CrossrefPubMedGoogle Scholar
  • 212 Charo I F, Myers S J, Herman A. et al . Molecular cloning and functional expression of two monocyte chemoattractant protein 1 receptors reveals alternative splicing of the carboxyl-terminal tails.  Proc Natl Acad Sci USA . 1994;  91 2752-2756
    PubMedGoogle Scholar
  • 213 Agostini C, Calabrese F, Rea F. et al . Cxcr3 and its ligand CXCL10 are expressed by inflammatory cells infiltrating lung allografts and mediate chemotaxis of T cells at sites of rejection.  Am J Pathol . 2001;  158 1703-1711
    PubMedGoogle Scholar
  • 214 Fischereder M, Luckow B, Hocher B. et al . CC chemokine receptor 5 and renal-transplant survival.  Lancet . 2001;  357 1758-1761
    CrossrefPubMedGoogle Scholar
  • 215 Martinson J J, Chapman N H, Rees D C. et al . Global distribution of the CCR5 gene 32-basepair deletion.  Nat Genet . 1997;  16 100-103
    PubMedGoogle Scholar
  • 216 Libert F, Cochaux P, Beckman G. et al . The deltaccr5 mutation conferring protection against HIV-1 in Caucasian populations has a single and recent origin in northeastern Europe.  Hum Mol Genet . 1998;  7 399-406
    CrossrefPubMedGoogle Scholar
  • 217 Stephens J C, Reich D E, Goldstein D B. et al . Dating the origin of the CCR5-Delta32 AIDS-resistance allele by the coalescence of haplotypes.  Am J Hum Genet . 1998;  62 1507-1515
    CrossrefPubMedGoogle Scholar
  • 218 Glanville A, Corris T, McNeil K D. Mycophenolate mofetil (MMF) vs azathioprine (AZA) in lung transplantation for the prevention of bronchiolitis obliterans syndrome (BOS): results of a 3-year international, randomised trial.  J Heart Lung Transplant . 2003;  22(S1) P207
    PubMedGoogle Scholar
  • 219 Glanville A R, Baldwin J C, Burke C M. et al . Obliterative bronchiolitis after heart-lung transplantation: apparent arrest by augmented immunosuppression.  Ann Intern Med . 1987;  107 300-304
    PubMedGoogle Scholar
  • 220 Kesten S, Chaparro C, Scavuzzo M. et al . Tacrolimus as rescue therapy for bronchiolitis obliterans syndrome.  J Heart Lung Transplant . 1997;  16 905-912
    PubMedGoogle Scholar
  • 221 Lynch III P J, McCune W J. Immunosuppressive and cytotoxic pharmacotherapy for pulmonary disorders.  Am J Respir Crit Care Med . 1997;  155 395-420
    PubMedGoogle Scholar
  • 222 Allen M D, Burke C M, McGregor C G. et al . Steroid-responsive bronchiolitis after human heart-lung transplantation.  J Thorac Cardiovasc Surg . 1986;  92(3 Pt 1) 449-451
    PubMedGoogle Scholar
  • 223 Verleden G M. Bronchiolitis obliterans syndrome after lung transplantation: medical treatment.  Monaldi Arch Chest Dis . 2000;  55 140-145
    PubMedGoogle Scholar
  • 224 Kesten S, Maidenberg A, Winton T. et al . Treatment of presumed and proven acute rejection following six months of lung transplant survival.  Am J Respir Crit Care Med . 1995;  152(4 Pt 1) 1321-1324
    CrossrefPubMedGoogle Scholar
  • 225 Shapiro R. Tacrolimus in solid organ transplantation: an update.  Transplant Proc . 1999;  31 2203-2205
    CrossrefPubMedGoogle Scholar
  • 226 Lake K D. Immunosuppressive drugs and novel strategies to prevent acute and chronic allograft rejection.  Semin Respir Crit Care Med . 2001;  22 559-580
    PubMedGoogle Scholar
  • 227 Pirsch J D, Miller J, Deierhoi M H. et al . A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group.  Transplantation . 1997;  63 977-983
    CrossrefPubMedGoogle Scholar
  • 228 Bismuth H. Comparison of FK 506- and cyclosporine-based immunosuppression: FK 506 therapy significantly reduces the incidence of acute, steroid-resistant, refractory, and chronic rejection whilst possessing a comparable safety profile. European FK 506 Multicentre Liver Study Group.  Transplant Proc . 1995;  27 45-49
    PubMedGoogle Scholar
  • 229 Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. European FK506 Multicentre Liver Study Group.  Lancet . 1994;  344 423-428
    PubMedGoogle Scholar
  • 230 Meiser B M, Uberfuhr P, Fuchs A. et al . Single-center randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of acute myocardial rejection.  J Heart Lung Transplant . 1998;  17 782-788
    PubMedGoogle Scholar
  • 231 Reichart B, Meiser B, Vigano M. et al . European Multicenter Tacrolimus (FK506) Heart Pilot Study: one-year results. European Tacrolimus Multicenter Heart Study Group.  J Heart Lung Transplant . 1998;  17 775-781
    PubMedGoogle Scholar
  • 232 Pham S M, Kormos R L, Hattler B G. et al . A prospective trial of tacrolimus (FK 506) in clinical heart transplantation: intermediate-term results.  J Thorac Cardiovasc Surg . 1996;  111 764-772
    PubMedGoogle Scholar
  • 233 Taylor D O, Barr M L, Radovancevic B. et al . A randomized, multicenter comparison of tacrolimus and cyclosporine immunosuppressive regimens in cardiac transplantation: decreased hyperlipidemia and hypertension with tacrolimus.  J Heart Lung Transplant . 1999;  18 336-345
    PubMedGoogle Scholar
  • 234 Jang H J, Kim S C, Han D J. Tacrolimus for rescue therapy in refractory renal allograft rejection.  Transplant Proc . 2000;  32 1765-1766
    CrossrefPubMedGoogle Scholar
  • 235 Reyes J, Jain A, Mazariegos G. et al . Long-term results after conversion from cyclosporine to tacrolimus in pediatric liver transplantation for acute and chronic rejection.  Transplantation . 2000;  69 2573-2580
    PubMedGoogle Scholar
  • 236 Yamani M H, Starling R C, Pelegrin D. et al . Efficacy of tacrolimus in patients with steroid-resistant cardiac allograft cellular rejection.  J Heart Lung Transplant . 2000;  19 337-342
    PubMedGoogle Scholar
  • 237 Reichenspurner H, Kur F, Treede H. et al . Tacrolimus-based immunosuppressive protocols in lung transplantation.  Transplantation Proceedings . 1999;  31 171-172
    CrossrefPubMedGoogle Scholar
  • 238 Keenan R J, Konishi H, Kawai A. et al . Clinical trial of tacrolimus versus cyclosporine in lung transplantation [see comments].  Annals of Thoracic Surgery . 1995;  60 580-585
    CrossrefPubMedGoogle Scholar
  • 239 Treede H, Kepetko W, Reichenspurner H. et al . Tacrolimus versus cyclosporine after lung transplantation: a prospective, open, randomized two-center trial comparing two different immunosuppressive protocols.  J Heart Lung Transplant . 2001;  20 511-517
    CrossrefPubMedGoogle Scholar
  • 240 Zuckermann A, Reichenspurner H, Jaksch P. et al . Long-term follow-up of a prospective randomized trial comparing tacrolimus versus cyclosporine in combination with MMF after lung transplantation.  J Heart Lung Transplant . 2003;  22(1S) S76-S77
    PubMedGoogle Scholar
  • 241 Reichenspurner H, Glanville A, Klepetko W. et al . Prospective randomized international, multicenter investigator driven study comparing TAC and CSA (==MMF/steroids) after lung transplantation: interim analysis of 110 patients.  J Heart Lung Transplant . 2003;  22(1S) S77
    PubMedGoogle Scholar
  • 242 Knoop C, Antoine M, Vachiery J L. et al . FK 506 rescue therapy for irreversible airway rejection in heart-lung transplant recipients: report on five cases.  Transplant Proc . 1994;  26 3240-3241
    PubMedGoogle Scholar
  • 243 Wiebe K, Harringer W, Franke U. et al . FK506 rescue therapy in lung transplantation.  Transplant Proc . 1998;  30 1508-1509
    CrossrefPubMedGoogle Scholar
  • 244 Mentzer Jr M R, Jahania M S, Lasley R D. Tacrolimus as a rescue immunosuppressant after heart and lung transplantation. The US Multicenter FK506 Study Group.  Transplantation . 1998;  65 109-113
    PubMedGoogle Scholar
  • 245 Onsager D R, Canver C C, Jahania M S. et al . Efficacy of tacrolimus in the treatment of refractory rejection in heart and lung transplant recipients.  J Heart Lung Transplant . 1999;  18 448-455
    PubMedGoogle Scholar
  • 246 Horning N R, Lynch J P, Sundaresan S R. et al . Tacrolimus therapy for persistent or recurrent acute rejection after lung transplantation.  J Heart Lung Transplant . 1998;  17 761-767
    PubMedGoogle Scholar
  • 247 Cairn J, Yek T, Banner N R. et al . Time-related changes in pulmonary function after conversion to tacrolimus in bronchiolitis obliterans syndrome.  J Heart Lung Transplant . 2003;  22 50-57
    CrossrefPubMedGoogle Scholar
  • 248 Ross D J, Lewis M I, Kramer M. et al . FK 506 “rescue” immunosuppression for obliterative bronchiolitis after lung transplantation.  Chest . 1997;  112 1175-1179
    PubMedGoogle Scholar
  • 249 Vitulo P, Oggionni T, Cascina A. et al . Efficacy of tacrolimus rescue therapy in refractory acute rejection after lung transplantation.  J Heart Lung Transplant . 2002;  21 435-439
    CrossrefPubMedGoogle Scholar
  • 250 Fieguth H G, Krueger S, Wiedenmann D E. et al . Tacrolimus for treatment of bronchiolitis obliterans syndrome after unilateral and bilateral lung transplantation.  Transplant Proc . 2002;  34 1884
    CrossrefPubMedGoogle Scholar
  • 251 Kesten S, Chaparro C, Scavuzzo M. et al . Tacrolimus as rescue therapy for bronchiolitis obliterans syndrome.  J Heart Lung Transplant . 1997;  16 905-912
    PubMedGoogle Scholar
  • 252 Lipson D A, Palevsky H I, Kotloff R M. et al . Conversion to tacrolimus (FK506) from cyclosporine after orthotopic lung transplantation.  Transplant Proc . 1998;  30 1505-1507
    CrossrefPubMedGoogle Scholar
  • 253 Klepetko W, Estenne M, Glanville A. et al . A multicenter study to assess outcome following a switch in the primary immunosuppressant from cyclosporin (CYA) to tacrolimus (TAC) in lung recipients.  J Heart Lung Transplant . 2001;  20 208
    PubMedGoogle Scholar
  • 254 Roman A, Bravo C, Monforte V. et al . Preliminary results of rescue therapy with tacrolimus and mycophenolate mofetil in lung transplanted patients with bronchiolitis obliterans.  Transplant Proc . 2002;  34 146-147
    CrossrefPubMedGoogle Scholar
  • 255 Sarahrudi K, Carretta A, Wisser W. et al . The value of switching from cyclosporine to tacrolimus in the treatment of refractory acute rejection and obliterative bronchiolitis after lung transplantation.  Transpl Int . 2002;  15 24-28
    CrossrefPubMedGoogle Scholar
  • 256 Revell M P, Lewis M E, Llewellyn-Jones C G. et al . Conservation of small-airway function by tacrolimus/cyclosporine conversion in the management of bronchiolitis obliterans following lung transplantation.  J Heart Lung Transplant . 2000;  19 1219-1223
    PubMedGoogle Scholar
  • 257 Sollinger H W. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. US Renal Transplant Mycophenolate Mofetil Study Group.  Transplantation . 1995;  60 225-232
    CrossrefPubMedGoogle Scholar
  • 258 A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group.  Transplantation . 1996;  61 1029-1037
    PubMedGoogle Scholar
  • 259 Kobashigawa J, Miller L, Renlund D. et al . A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Mycophenolate Mofetil Investigators Transplantation .  1998;  66 507-515
    CrossrefPubMedGoogle Scholar
  • 260 Ross D J, Waters P F, Levine M. et al . Mycophenolate mofetil versus azathioprine immunosuppressive regimens after lung transplantation: preliminary experience.  J Heart Lung Transplant . 1998;  17 768-774
    PubMedGoogle Scholar
  • 261 Zuckermann A, Klepetko W, Birsan T. et al . Comparison between mycophenolate mofetil- and azathioprine-based immunosuppressions in clinical lung transplantation.  J Heart Lung Transplant . 1999;  18 432-440
    PubMedGoogle Scholar
  • 262 O'Hair D P, Cantu E, McGregor C. et al . Preliminary experience with mycophenolate mofetil used after lung transplantation.  J Heart Lung Transplant . 1998;  17 864-868
    PubMedGoogle Scholar
  • 263 Dunitz J, Hertz M I, Park S J. The risk of bronchiolitis obliterans syndrome is reduced in lung transplant patients who receive mycophenolate mofetil based immunosuppression.  J Heart Lung Transplant . 2003;  22(S1) S151
    PubMedGoogle Scholar
  • 264 Palmer S M, Baz M A, Sanders L. et al . Results of a randomized, prospective, multicenter trial of mycophenolate mofetil versus azathioprine in the prevention of acute lung allograft rejection.  Transplantation . 2001;  71 1772-1776
    CrossrefPubMedGoogle Scholar
  • 265 Bodin L, Grenet D, Gonin F. et al . Cyclosporin C2 monotoring after lung transplantation (LT) in cystic fibrosis (CF) and non CF patients.  J Heart Lung Transplant . 2003;  22(S1) P120
    PubMedGoogle Scholar
  • 266 Kaplan B, Meier-Kriesche H U, Friedman G. et al . The effect of renal insufficiency on mycophenolic acid protein binding.  J Clin Pharmacol . 1999;  39 715-720
    CrossrefPubMedGoogle Scholar
  • 267 Shaw L M, Korecka M, van Breeman R. et al . Analysis, pharmacokinetics and therapeutic drug monitoring of mycophenolic acid.  Clin Biochem . 1998;  31 323-328
    PubMedGoogle Scholar
  • 268 Seebacher G, Mallinger R, Laufer G. et al . Pharmacokinetics of mycophenolate mofetil in heart transplant recipients.  Adv Exp Med Biol . 1998;  431 801-803
    PubMedGoogle Scholar
  • 269 Muller M M, Vogl M, Griesmacher A. Mycophenolic acid monitoring in HTX patients: a preliminary report.  Therapie . 1997;  52 341-344
    PubMedGoogle Scholar
  • 270 Dubrey S W, Holt D W, Banner N. Measurement of mycophenolate mofetil plasma levels after heart transplantation and a potential side effect of high levels.  Ther Drug Monit . 1999;  21 325-326
    CrossrefPubMedGoogle Scholar
  • 271 Shaw L M, Kaplan B, DeNofrio D. et al . Pharmacokinetics and concentration-control investigations of mycophenolic acid in adults after transplantation.  Ther Drug Monit . 2000;  22 14-19
    CrossrefPubMedGoogle Scholar
  • 272 Shaw L M, Korecka M, DeNofrio D. et al . Pharmacokinetic, pharmacodynamic, and outcome investigations as the basis for mycophenolic acid therapeutic drug monitoring in renal and heart transplant patients.  Clin Biochem . 2001;  34 17-22
    PubMedGoogle Scholar
  • 273 Ensom M H, Partovi N, Decarie D. et al . Pharmacokinetics and protein binding of mycophenolic acid in stable lung transplant recipients.  Ther Drug Monit . 2002;  24 310-314
    CrossrefPubMedGoogle Scholar
  • 274 Partovi N, Ensom M H, Fradet G. et al . Factors influence mycophenolate mofetil drug exposure in thoracic organ transplant recipients.  J Heart Lung Transplant . 2003;  22(S1) S121
    PubMedGoogle Scholar
  • 275 DeNofrio D, Loh E, Kao A. et al . Mycophenolic acid concentration are assocated with cardiac allograft rejection.  J Heart Lung Transplant . 2000;  19 1071-1076
    PubMedGoogle Scholar
  • 276 Meiser B M, Pfeiffer M, Schmidt D. et al . Combination therapy with tacrolimus and mycophenolate mofetil following cardiac transplantation: importance of mycophenolic acid therapeutic drug monitoring.  J Heart Lung Transplant . 1999;  18 143-149
    PubMedGoogle Scholar
  • 277 Meiser B M, Pfeiffer M, Schmidt D. et al . The efficacy of the combination of tacrolimus and mycophenolate mofetil for prevention of acute myocardial rejection is dependent on routine monitoring of mycophenolic acid trough acid levels.  Transplant Proc . 1999;  31 84-87
    PubMedGoogle Scholar
  • 278 Meiser B M, Schmidt D, Pfeiffer M. et al .MMF-dose adjustments based on MPA-trough levels after heart transplantation: difference between high and low dose pharmacokinetics. AST Eighteenth Annual Meeting 1999. S110.
    Google Scholar
  • 279 Devyatko E, Ploner M, Zuckermann A. et al . Value of mycophenolic acid trough level monitoring after lung transplantation.  Transplant Proc . 2002;  34 1881-1883
    CrossrefPubMedGoogle Scholar
  • 280 Speich R, Boehler A, Thurnheer R. et al . Salvage therapy with mycophenolate mofetil for lung transplant bronchiolitis obliterans: importance of dosage.  Transplantation . 1997;  64 533-535
    CrossrefPubMedGoogle Scholar
  • 281 Whyte R I, Rossi S J, Mulligan M S. et al . Mycophenolate mofetil for obliterative bronchiolitis syndrome after lung transplantation.  Ann Thorac Surg . 1997;  64 945-948
    CrossrefPubMedGoogle Scholar
  • 282 Dupont L J, Delcroix M, Vanhaecke D. et al . Azathioprine/mycophenolate conversions in the managment of bronchiolitis obliterans syndrome (BOS) following (heart-) lung transplantation.  J Heart Lung Transplant . 2003;  22(1S) S123
    PubMedGoogle Scholar
  • 283 Sehgal S N. Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression.  Clin Biochem . 1998;  31 335-340
    CrossrefPubMedGoogle Scholar
  • 284 Poston R S, Billingham M, Hoyt E G. et al . Rapamycin reverses chronic graft vascular disease in a novel cardiac allograft model.  Circulation . 1999;  100 67-74
    PubMedGoogle Scholar
  • 285 Viklicky O, Zou H, Muller V. et al . SDZ-RAD prevents manifestation of chronic rejection in rat renal allografts.  Transplantation . 2000;  69 497-502
    PubMedGoogle Scholar
  • 286 Fahrni J A, Berry G J, Morris R E. et al . Rapamycin inhibits development of obliterative airway disease in a murine heterotopic airway transplant model.  Transplantation . 1997;  63 533-537
    PubMedGoogle Scholar
  • 287 Salminen U S, Maasilta P K, Taskinen E I. et al . Prevention of small airway obliteration in a swine heterotopic lung allograft model.  J Heart Lung Transplant . 2000;  19 193-206
    PubMedGoogle Scholar
  • 288 Cahill B C, Somerville K T, Crompton J A. et al . Early experience with sirolimus in lung transplant recipients with chronic allograft rejection.  J Heart Lung Transplant . 2003;  22 169-176
    CrossrefPubMedGoogle Scholar
  • 289 Snell G I, Valentine V, Love R. et al . One-year results of an international, ransomized, double-blind study of everolimus vs azathioprine as adjunctive therapy to inhibit the decline of pulmonary function in stable lung or heart/lung transplant recipients.  J Heart Lung Transplant . 2003;  22(S1) S207-S208
    PubMedGoogle Scholar
  • 290 Cooper J D, Patterson G A, Trulock E P. Results of single and bilateral lung transplantation in 131 consecutive recipients. Washington University Lung Transplant Group.  J Thorac Cardiovasc Surg . 1994;  107 460-470
    PubMedGoogle Scholar
  • 291 Paradis I, Yousem S, Griffith B. Airway obstruction and bronchiolitis obliterans after lung transplantation.  Clin Chest Med . 1993;  14 751-763
    PubMedGoogle Scholar
  • 292 A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. Ortho Multicenter Transplant Study Group.  N Engl J Med . 1985;  313 337-342
    PubMedGoogle Scholar
  • 293 Aubock J, Irschick E, Romani N. et al . Rejection, after a slightly prolonged survival time, of Langerhans' cell-free allogeneic cultured epidermis used for wound coverage in humans.  Transplantation . 1988;  45 730-737
    PubMedGoogle Scholar
  • 294 O'Connell J B, Renlund D G, Gay Jr A W. et al . Efficacy of OKT3 retreatment for refractory cardiac allograft rejection.  Transplantation . 1989;  47 788-792
    PubMedGoogle Scholar
  • 295 Ross D J, Jordan S C, Nathan S D. et al . Delayed development of obliterative bronchiolitis syndrome with OKT3 after unilateral lung transplantation: a plea for multicenter immunosuppressive trials Chest .  1996;  109 870-873
    PubMedGoogle Scholar
  • 296 Shennib H, Massard G, Reynaud M. et al . Efficacy of OKT3 therapy for acute rejection in isolated lung transplantation.  J Heart Lung Transplant . 1994;  13 514-519
    PubMedGoogle Scholar
  • 297 Date H, Lynch III P J, Sundaresan S. et al . The impact of cytolytic therapy on bronchiolitis obliterans syndrome.  J Heart Lung Transplant . 1998;  17 869-875
    PubMedGoogle Scholar
  • 298 Kesten S, Rajagopalan N, Maurer J. Cytolytic therapy for the treatment of bronchiolitis obliterans syndrome following lung transplantation.  Transplantation . 1996;  61 427-430
    CrossrefPubMedGoogle Scholar
  • 299 Nashan B, Light S, Hardie I R. et al . Reduction of acute renal allograft rejection by daclizumab. Daclizumab Double Therapy Study Group.  Transplantation . 1999;  67 110-115
    PubMedGoogle Scholar
  • 300 Vincenti F, Kirkman R, Light S. et al . Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group.  N Engl J Med . 1998;  338 161-165
    CrossrefPubMedGoogle Scholar
  • 301 Beniaminovitz A, Itescu S, Lietz K. et al . Prevention of rejection in cardiac transplantation by blockade of the interleukin-2 receptor with a monoclonal antibody.  N Engl J Med . 2000;  342 613-619
    CrossrefPubMedGoogle Scholar
  • 302 Berard J L, Velez R L, Freeman R B. et al . A review of interleukin-2 receptor antagonists in solid organ transplantation.  Pharmacotherapy . 1999;  19 1127-1137
    CrossrefPubMedGoogle Scholar
  • 303 Nashan B, Schwinzer R, Schlitt H J. et al . Immunological effects of the anti-IL-2 receptor monoclonal antibody BT 563 in liver allografted patients.  Transpl Immunol . 1995;  3 203-211
    PubMedGoogle Scholar
  • 304 Brock M V, Borja M C, Ferber L. et al . Induction therapy in lung transplantation: a prospective, controlled clinical trial comparing OKT3, anti-thymocyte globulin, and daclizumab.  J Heart Lung Transplant . 2001;  20 1282-1290
    CrossrefPubMedGoogle Scholar
  • 305 Garrity Jr R E, Villanueva J, Bhorade S M. et al . Low rate of acute lung allograft rejection after the use of daclizumab, an interleukin-2 receptor antibody.  Transplantation . 2001;  71 773-777
    PubMedGoogle Scholar
  • 306 Marom E M, Choi Y W, Palmer S M. et al . Reperfusion edema after lung transplantation: effect of daclizumab.  Radiology . 2001;  221 508-514
    PubMedGoogle Scholar
  • 307 Shaddy R E, Bullock E A, Tani L Y. et al . Methotrexate therapy in pediatric heart transplantation as treatment of recurrent mild to moderate acute cellular rejection.  J Heart Lung Transplant . 1994;  13 1009-1013
    PubMedGoogle Scholar
  • 308 Bourge R C, Kirklin J K, White-Williams C. et al . Methotrexate pulse therapy in the treatment of recurrent acute heart rejection.  J Heart Lung Transplant . 1992;  11 1116-1124
    PubMedGoogle Scholar
  • 309 Olsen S L, O'Connell J B, Bristow M R. et al . Methotrexate as an adjunct in the treatment of persistent mild cardiac allograft rejection.  Transplantation . 1990;  50 773-775
    PubMedGoogle Scholar
  • 310 Ferraro P, Carrier M, White M. et al . Antithymocyte globulin and methotrexate therapy of severe or persistent cardiac allograft rejection.  Ann Thorac Surg . 1995;  60 372-376
    CrossrefPubMedGoogle Scholar
  • 311 Michael B, Francos G C, Burke Jr F J. et al . Methotrexate is effective in preventing acute and potentially chronic renal allograft rejection.  Transplant Proc . 1994;  26 3046-3047
    PubMedGoogle Scholar
  • 312 Cahill B C, O'Rourke M K, Strasburg K A. et al . Methotrexate for lung transplant recipients with steroid-resistant acute rejection.  J Heart Lung Transplant . 1996;  15 1130-1137
    PubMedGoogle Scholar
  • 313 Komatsu K, Youm W, Konishi H. et al . Prolonged survival of hamster-to-rat pulmonary xenografts by tacrolimus (FK506) and cyclophosphamide.  J Heart Lung Transplant . 1996;  15 722-727
    PubMedGoogle Scholar
  • 314 Miller L W, Wesp A, Jennison S H. et al . Vascular rejection in heart transplant recipients.  J Heart Lung Transplant . 1993;  12 S147-S152
    PubMedGoogle Scholar
  • 315 Verleden G M, Buyse B, Delcroix M. et al . Cyclophosphamide rescue therapy for chronic rejection after lung transplantation.  J Heart Lung Transplant . 1999;  18 1139-1142
    CrossrefPubMedGoogle Scholar
  • 316 Evans M A, Schomberg P J, Rodeheffer R J. et al . Total lymphoid irradiation: a novel and successful therapy for resistant cardiac allograft rejection.  Mayo Clin Proc . 1992;  67 785-790
    PubMedGoogle Scholar
  • 317 Frist W H, Winterland A W, Gerhardt E B. et al . Total lymphoid irradiation in heart transplantation: adjunctive treatment for recurrent rejection.  Ann Thorac Surg . 1989;  48 863-864
    PubMedGoogle Scholar
  • 318 Hunt S A, Strober S, Hoppe R T. et al . Total lymphoid irradiation for treatment of intractable cardiac allograft rejection.  J Heart Lung Transplant . 1991;  10 211-216
    PubMedGoogle Scholar
  • 319 Levin B, Bohannon L, Warvariv V. et al . Total lymphoid irradiation (TLI) in the cyclosporine era: use of TLI in resistant cardiac allograft rejection.  Transplant Proc . 1989;  21(1 Pt 2) 1793-1795
    PubMedGoogle Scholar
  • 320 Salter M M, Kirklin J K, Bourge R C. et al . Total lymphoid irradiation in the treatment of early or recurrent heart rejection.  J Heart Lung Transplant . 1992;  11 902-911
    PubMedGoogle Scholar
  • 321 O'Hagan A R, Stillwell P C, Arroliga A. et al . Photopheresis in the treatment of refractory bronchiolitis obliterans complicating lung transplantation.  Chest . 1999;  115 1459-1462
    CrossrefPubMedGoogle Scholar
  • 322 Diamond D A, Michalski J M, Lynch III P J. et al . Efficacy of total lymphoid irradiation for chronic allograft rejection following bilateral lung transplantation.  Int J Radiat Oncol Biol Phys . 1998;  41 795-800
    CrossrefPubMedGoogle Scholar
  • 323 Valentine V G, Robbins R C, Wehner J H. et al . Total lymphoid irradiation for refractory acute rejection in heart-lung and lung allografts Chest .  1996;  109 1184-1189
    CrossrefPubMedGoogle Scholar
  • 324 Chin C, Hunt S, Robbins R. et al . Long-term follow-up after total lymphoid irradiation in pediatric heart transplant recipients.  J Heart Lung Transplant . 2002;  21 667-673
    PubMedGoogle Scholar
  • 325 Perez M, Edelson R, Laroche L. et al . Inhibition of antiskin allograft immunity by infusions with syngeneic photoinactivated effector lymphocytes.  J Invest Dermatol . 1989;  92 669-676
    CrossrefPubMedGoogle Scholar
  • 326 Edelson R, Berger C, Gasparro F. et al . Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy: preliminary results.  N Engl J Med . 1987;  316 297-303
    CrossrefPubMedGoogle Scholar
  • 327 Barr M L, Meiser B M, Eisen H J. et al . Photopheresis for the prevention of rejection in cardiac transplantation. Photopheresis Transplantation Study Group.  N Engl J Med . 1998;  339 1744-1751
    CrossrefPubMedGoogle Scholar
  • 328 Dall'Amico R, Montini G, Murer L. et al . Benefits of photopheresis in the treatment of heart transplant patients with multiple/refractory rejection.  Transplant Proc . 1997;  29 609-611
    CrossrefPubMedGoogle Scholar
  • 329 Costanzo-Nordin M R, Hubbell E A, O'Sullivan E J. et al . Successful treatment of heart transplant rejection with photopheresis.  Transplantation . 1992;  53 808-815
    CrossrefPubMedGoogle Scholar
  • 330 Lehrer M S, Rook A H, Tomaszewski J E. et al . Successful reversal of severe refractory cardiac allograft rejection by photopheresis.  J Heart Lung Transplant . 2001;  20 1233-1236
    PubMedGoogle Scholar
  • 331 Wieland M, Thiede V L, Strauss R G. et al . Treatment of severe cardiac allograft rejection with extracorporeal photochemotherapy.  J Clin Apheresis . 1994;  9 171-175
    PubMedGoogle Scholar
  • 332 Wise B V, King K E, Rook A H. et al . Extracorporeal photopheresis in the treatment of persistent rejection in a pediatric lung transplant recipient.  Prog Transplant . 2003;  13 61-64
    PubMedGoogle Scholar
  • 333 Andreu G, Achkar A, Couetil J P. et al . Extracorporeal photochemotherapy treatment for acute lung rejection episode.  J Heart Lung Transplant . 1995;  14 793-796
    PubMedGoogle Scholar
  • 334 Heshmati F, Guillemain R, Achkar A. et al . Traitement du rejet de greffe d'organe par photochimiotherapie extra-corporelle.  Ann Med Interne (Paris) . 1994;  145 312-315
    PubMedGoogle Scholar
  • 335 Slovis B S, Loyd J E, King Jr E L. Photopheresis for chronic rejection of lung allografts.  N Engl J Med . 1995;  332 962
    CrossrefPubMedGoogle Scholar
  • 336 Keenan R J, Zeevi A, Iacono A T. et al . Efficacy of inhaled cyclosporine in lung transplant recipients with refractory rejection: correlation of intragraft cytokine gene expression with pulmonary function and histologic characteristics.  Surgery . 1995;  118 385-391
    PubMedGoogle Scholar
  • 337 O'Riordan T G, Iacono A, Keenan R J. et al . Delivery and distribution of aerosolized cyclosporine in lung allograft recipients.  Am J Respir Crit Care Med . 1995;  151(2 Pt 1) 516-521
    PubMedGoogle Scholar
  • 338 Iacono A T, Smaldone G C, Keenan R J. et al . Dose-related reversal of acute lung rejection by aerosolized cyclosporine.  Am J Respir Crit Care Med . 1997;  155 1690-1698
    PubMedGoogle Scholar
  • 339 Keenan R J, Iacono A, Dauber J H. et al . Treatment of refractory acute allograft rejection with aerosolized cyclosporine in lung transplant recipients.  J Thorac Cardiovasc Surg . 1997;  113 335-340
    PubMedGoogle Scholar
  • 340 Corcoran T, Smaldone G C, Dauber J. et al . Aerosol cyclosporine provides dose dependent improvement in lung function after lung transplantation.  J Heart Lung Transplant . 2003;  22 (suppl 1) S77
    PubMedGoogle Scholar
  • 341 De Soyza A, Fisher A J, Small T. et al . Inhaled corticosteroids and the treatment of lymphocytic bronchiolitis following lung transplantation.  Am J Respir Crit Care Med . 2001;  164 1209-1212
    CrossrefPubMedGoogle Scholar
  • 342 Takao M, Higenbottam T W, Audley T. et al . Effects of inhaled nebulized steroids (budesonide) on acute and chronic lung function in heart-lung transplant patients.  Transplant Proc . 1995;  27 1284-1285
    PubMedGoogle Scholar
  • 343 Whitford H, Walters E H, Levvey B. et al . Addition of inhaled corticosteroids to systemic immunosuppression after lung transplantation: a double-blind, placebo-controlled trial.  Transplantation . 2002;  73 1793-1799
    CrossrefPubMedGoogle Scholar
  • 344 Rubin B K, Tamaoki J. Macrolide antibiotics as biological response modifiers.  Curr Opin Investig Drugs . 2000;  1 169-172
    PubMedGoogle Scholar
  • 345 Culic O, Erakovic V, Parnham M J. Anti-inflammatory effects of macrolide antibiotics.  Eur J Pharmacol . 2001;  429 209-229
    CrossrefPubMedGoogle Scholar
  • 346 Kadota J, Sakito O, Kohno S. et al . A mechanism of erythromycin treatment in patients with diffuse panbronchiolitis.  Am Rev Respir Dis . 1993;  147 153-159
    PubMedGoogle Scholar
  • 347 Kudoh S, Azuma A, Yamamoto M. et al . Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin.  Am J Respir Crit Care Med . 1998;  157(6 Pt 1) 1829-1832
    CrossrefPubMedGoogle Scholar
  • 348 Equi A, Balfour-Lynn I M, Bush A. et al . Long-term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial.  Lancet . 2002;  360 978-984
    CrossrefPubMedGoogle Scholar
  • 349 Wolter J, Seeney S, Bell S. et al . Effect of long-term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial.  Thorax . 2002;  57 212-216
    CrossrefPubMedGoogle Scholar
  • 350 Gerhardt S G, McDyer J F, Girgis R E. et al . Maintenance azithromycin therapy for bronchiolitis obliterans syndrome: results of a pilot study.  Am J Respir Crit Care Med . 2003;  168 121-125
    CrossrefPubMedGoogle Scholar
  • 351 Ward W F, Molteni A, Ts'ao C H. et al . Radiation pneumotoxicity in rats: modification by inhibitors of angiotensin converting enzyme.  Int J Radiat Oncol Biol Phys . 1992;  22 623-625
    PubMedGoogle Scholar
  • 352 Kobayashi J, Crawford S E, Backer C L. et al . Captopril reduces graft coronary artery disease in a rat heterotopic transplant model.  Circulation . 1993;  88(5 Pt 2) II286-II290
    PubMedGoogle Scholar
  • 353 Crawford S E, Huang L, Hsueh W. et al . Captopril and platelet-activating factor (PAF) antagonist prevent cardiac allograft vasculopathy in rats: role of endogenous PAF and PAF-like compounds.  J Heart Lung Transplant . 1999;  18 470-477
    PubMedGoogle Scholar
  • 354 Maclean A A, Liu M, Fischer S. et al . Targeting the angiotensin system in posttransplant airway obliteration: the antifibrotic effect of angiotensin converting enzyme inhibition.  Am J Respir Crit Care Med . 2000;  162 310-315
    PubMedGoogle Scholar
  • 355 Mach F. Immunosuppressive effects of statins.  Atheroscler Suppl . 2002;  3 17-20
    PubMedGoogle Scholar
  • 356 Kobashigawa J A, Katznelson S, Laks H. et al . Effect of pravastatin on outcomes after cardiac transplantation.  N Engl J Med . 1995;  333 621-627
    PubMedGoogle Scholar
  • 357 Johnson B A, Iacono A T, Zeevi A. et al . Statin use is associated with improved function and survival of lung allografts.  Am J Respir Crit Care Med . 2003;  167 1271-1278
    CrossrefPubMedGoogle Scholar
  • 358 Wenke K, Meiser B, Thiery J. et al . Simvastatin reduces graft vessel disease and mortality after heart transplantation: a four-year randomized trial.  Circulation . 1997;  96 1398-1402
    PubMedGoogle Scholar
  • 359 Kasiske B L, Heim-Duthoy K L, Singer G G. et al . The effects of lipid-lowering agents on acute renal allograft rejection.  Transplantation . 2001;  72 223-227
    PubMedGoogle Scholar
  • 360 Holdaas H, Jardine A G, Wheeler D C. et al . Effect of fluvastatin on acute renal allograft rejection: a randomized multicenter trial.  Kidney Int . 2001;  60 1990-1997
    PubMedGoogle Scholar
  • 361 Sahu K, Sharma R, Gupta A. et al . Effect of lovastatin, an HMG CoA reductase inhibitor, on acute renal allograft rejection.  Clin Transplant . 2001;  15 173-175
    CrossrefPubMedGoogle Scholar
  • 362 Calne R, Moffatt S D, Friend P J. et al . Campath IH allows low-dose cyclosporine monotherapy in 31 cadaveric renal allograft recipients.  Transplantation . 1999;  68 1613-1616
    PubMedGoogle Scholar
  • 363 Rebello P R, Hale G, Friend P J. et al . Anti-globulin responses to rat and humanized CAMPATH-1 monoclonal antibody used to treat transplant rejection.  Transplantation . 1999;  68 1417-1420
    PubMedGoogle Scholar
  • 364 Reams B D, Davis R D, Curl J. et al . Treatment of refractory acute rejection in a lung transplant recipient with campath 1H.  Transplantation . 2002;  74 903-904
    CrossrefPubMedGoogle Scholar
      >